Warning: The NCBI web site requires JavaScript to function. more...
Fetching bibliography...
Generate a file for use with external citation management software.
HCV RNA Levels Following Virologic Failure with Direct-Acting Antivirals: Implications for Lower Sensitivity Diagnostic Assays.
Harrington PR, Komatsu TE, Sun H, Naeger LK.
Clin Infect Dis. 2019 May 10. pii: ciz385. doi: 10.1093/cid/ciz385. [Epub ahead of print]
Similar articles
HCV genotype 4, 5 and 6: Distribution of viral subtypes and sustained virologic response rates in clinical trials of approved direct-acting antiviral regimens.
Boyd SD, Harrington P, Komatsu TE, Naeger LK, Chan-Tack K, Murray J, Birnkrant D, Struble K.
J Viral Hepat. 2018 Aug;25(8):969-975. doi: 10.1111/jvh.12896. Epub 2018 May 8.
Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectives.
Harrington PR, Komatsu TE, Deming DJ, Donaldson EF, O'Rear JJ, Naeger LK.
Hepatology. 2018 Jun;67(6):2430-2448. doi: 10.1002/hep.29693.
Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation.
Struble K, Chan-Tack K, Qi K, Naeger LK, Birnkrant D.
Hepatology. 2018 Feb;67(2):482-491. doi: 10.1002/hep.29601. Epub 2018 Jan 1.
Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.
Komatsu TE, Boyd S, Sherwat A, Tracy L, Naeger LK, O'Rear JJ, Harrington PR.
Gastroenterology. 2017 Feb;152(3):586-597. doi: 10.1053/j.gastro.2016.10.017. Epub 2016 Oct 20.
Effect of dolutegravir functional monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant patients.
Naeger LK, Harrington P, Komatsu T, Deming D.
Antivir Ther. 2016;21(6):481-488. doi: 10.3851/IMP3033. Epub 2016 Feb 11.
Regulatory evaluation of antiviral drug resistance in the era of next-generation sequencing.
Donaldson EF, Deming DJ, O'Rear JJ, Naeger LK.
Biomark Med. 2015;9(11):1047-51. doi: 10.2217/bmm.15.63. Epub 2015 Oct 28. No abstract available.
Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials.
Harrington PR, Deming DJ, Komatsu TE, Naeger LK.
Clin Infect Dis. 2015 Aug 15;61(4):666-7. doi: 10.1093/cid/civ402. Epub 2015 May 22. No abstract available.
FDA perspective on sofosbuvir therapy for patients with chronic hepatitis C virus genotype 1 infection who did not respond to treatment with pegylated interferon and ribavirin.
Mishra P, Florian J, Qi K, Zeng W, Naeger LK, Donaldson E, Connelly S, O'Rear J, Price D, Murray J, Birnkrant D.
Gastroenterology. 2014 Dec;147(6):1196-200. doi: 10.1053/j.gastro.2014.10.027. Epub 2014 Oct 27. No abstract available.
Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir.
Donaldson EF, Harrington PR, O'Rear JJ, Naeger LK.
Hepatology. 2015 Jan;61(1):56-65. doi: 10.1002/hep.27375. Epub 2014 Nov 20.
Resistance of human cytomegalovirus to ganciclovir/valganciclovir: a comprehensive review of putative resistance pathways.
Komatsu TE, Pikis A, Naeger LK, Harrington PR.
Antiviral Res. 2014 Jan;101:12-25. doi: 10.1016/j.antiviral.2013.10.011. Epub 2013 Oct 31. Review.
Reply: To PMID 22095516.
Harrington PR, Naeger LK, Zeng W.
Hepatology. 2013 Feb;57(2):856. doi: 10.1002/hep.25948. No abstract available.
Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment.
Harrington PR, Zeng W, Naeger LK.
Hepatology. 2012 Apr;55(4):1048-57. doi: 10.1002/hep.24791. Epub 2012 Mar 1.
Running a tightrope: regulatory challenges in the development of antiretrovirals.
Naeger LK, Struble KA, Murray JS, Birnkrant DB.
Antiviral Res. 2010 Jan;85(1):232-40. doi: 10.1016/j.antiviral.2009.07.016. Epub 2009 Aug 7. Review.
Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients.
Naeger LK, Struble KA.
AIDS. 2007 Jan 11;21(2):179-85.
Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients.
AIDS. 2006 Apr 4;20(6):847-53.
Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir.
Tuske S, Sarafianos SG, Clark AD Jr, Ding J, Naeger LK, White KL, Miller MD, Gibbs CS, Boyer PL, Clark P, Wang G, Gaffney BL, Jones RA, Jerina DM, Hughes SH, Arnold E.
Nat Struct Mol Biol. 2004 May;11(5):469-74. Epub 2004 Apr 25.
Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations.
White KL, Chen JM, Margot NA, Wrin T, Petropoulos CJ, Naeger LK, Swaminathan S, Miller MD.
Antimicrob Agents Chemother. 2004 Mar;48(3):992-1003.
Distinct requirements for the naturally occurring splice forms Stat4alpha and Stat4beta in IL-12 responses.
Hoey T, Zhang S, Schmidt N, Yu Q, Ramchandani S, Xu X, Naeger LK, Sun YL, Kaplan MH.
EMBO J. 2003 Aug 15;22(16):4237-48.
Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.
White KL, Margot NA, Wrin T, Petropoulos CJ, Miller MD, Naeger LK.
Antimicrob Agents Chemother. 2002 Nov;46(11):3437-46.
Th1 cells regulate hematopoietic progenitor cell homeostasis by production of oncostatin M.
Broxmeyer HE, Bruns HA, Zhang S, Cooper S, Hangoc G, McKenzie AN, Dent AL, Schindler U, Naeger LK, Hoey T, Kaplan MH.
Immunity. 2002 Jun;16(6):815-25.
ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase.
Naeger LK, Margot NA, Miller MD.
Antimicrob Agents Chemother. 2002 Jul;46(7):2179-84.
Mechanisms of HIV-1 nucleoside reverse transcriptase inhibitor resistance: is it all figured out?
Naeger LK, Miller MD.
Curr Opin Investig Drugs. 2001 Mar;2(3):335-9. Review.
Tenofovir (PMPA) is less susceptible to pyrophosphorolysis and nucleotide-dependent chain-terminator removal than zidovudine or stavudine.
Nucleosides Nucleotides Nucleic Acids. 2001 Apr-Jul;20(4-7):635-9.
Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
Antivir Ther. 2001 Jun;6(2):115-26.
E2F-Rb complexes assemble and inhibit cdc25A transcription in cervical carcinoma cells following repression of human papillomavirus oncogene expression.
Wu L, Goodwin EC, Naeger LK, Vigo E, Galaktionov K, Helin K, DiMaio D.
Mol Cell Biol. 2000 Oct;20(19):7059-67.
Bovine papillomavirus E2 protein activates a complex growth-inhibitory program in p53-negative HT-3 cervical carcinoma cells that includes repression of cyclin A and cdc25A phosphatase genes and accumulation of hypophosphorylated retinoblastoma protein.
Naeger LK, Goodwin EC, Hwang ES, DeFilippis RA, Zhang H, DiMaio D.
Cell Growth Differ. 1999 Jun;10(6):413-22.
Identification of a STAT4 binding site in the interleukin-12 receptor required for signaling.
Naeger LK, McKinney J, Salvekar A, Hoey T.
J Biol Chem. 1999 Jan 22;274(4):1875-8.
Transactivation-competent bovine papillomavirus E2 protein is specifically required for efficient repression of human papillomavirus oncogene expression and for acute growth inhibition of cervical carcinoma cell lines.
Goodwin EC, Naeger LK, Breiding DE, Androphy EJ, DiMaio D.
J Virol. 1998 May;72(5):3925-34.
Activation of the endogenous p53 growth inhibitory pathway in HeLa cervical carcinoma cells by expression of the bovine papillomavirus E2 gene.
Hwang ES, Naeger LK, DiMaio D.
Oncogene. 1996 Feb 15;12(4):795-803.
NS2 is required for efficient translation of viral mRNA in minute virus of mice-infected murine cells.
Naeger LK, Salomé N, Pintel DJ.
J Virol. 1993 Feb;67(2):1034-43.
Nonsense mutations inhibit splicing of MVM RNA in cis when they interrupt the reading frame of either exon of the final spliced product.
Naeger LK, Schoborg RV, Zhao Q, Tullis GE, Pintel DJ.
Genes Dev. 1992 Jun;6(6):1107-19.
The pathogenesis of infection with minute virus of mice depends on expression of the small nonstructural protein NS2 and on the genotype of the allotropic determinants VP1 and VP2.
Brownstein DG, Smith AL, Johnson EA, Pintel DJ, Naeger LK, Tattersall P.
J Virol. 1992 May;66(5):3118-24.
The small nonstructural protein (NS2) of the parvovirus minute virus of mice is required for efficient DNA replication and infectious virus production in a cell-type-specific manner.
Naeger LK, Cater J, Pintel DJ.
J Virol. 1990 Dec;64(12):6166-75.
Filters: Manage Filters